Lipitension: new options of combination therapy

Česká verzia

Authors: Martin Čaprnda ¹; Peter Kromka ^1,2; Juraj Tomášik ^3,4
Authors place of work: I. interná klinika LF UK a UNB, Nemocnica Staré Mesto, Bratislava ¹; III. interná klinika LF UK a UNB, Nemocnica akad. L. Dérera, Bratislava ²; Klinika ústnej, čeľustnej a tvárovej chirurgie LF UK a UNB, Nemocnica Ružinov, Bratislava ³; FortClinic, s. r. o., Bratislava ⁴
Published in the journal: AtheroRev 2023; 8(1): 25-31
Category: Reviews

Summary

Atherosclerosis-related cardiovascular (CV) diseases are the main cause of morbidity and mortality. Among the most important modifiable risk factors for atherosclerosis are arterial hypertension and dyslipidemia. Their concurrent presence can be characterized by the term “lipitension”. The presence of lipitension has a multiplicative effect on CV risk, therefore, in the case of simultaneous treatment of arterial hypertension and dyslipidemia, a significant synergistic decrease in CV risk can be expected. Ramipril as a representative of the group of ACE inhibitors and rosuvastatin are widely used for the treatment of arterial hypertension and dyslipidemia. The use of a new fixed combination of ramipril and rosuvastatin (Rosuramlon) may lead to improved adherence to treatment and a more significant decrease in CV risk. Rosuramlon is suitable for patients with mild and moderate arterial hypertension and dyslipidemia and can be combined with other antihypertensive and hypolipidemic agents.

Keywords:

arterial hypertension – dyslipidemia – fixed combination – lipitension – ramipril – rosuvastatin

Zdroje

1. World Health Organization. World Health Statistics 2012. WHO Press: Geneva 2012. ISBN 978–92–4-156444–1. Dostupné z WWW: <https:// www.who.int/docs/default-source/gho-documents/world-health-statistic- reports/world-health-statistics-2012.pdf>.

2. Khan MA, Hashim MJ, Mustafa H et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus 2020; 12(7): e9349. Dostupné z DOI: <http://dx.doi.org/10.7759/ cureus.9349>.

3. Borghi C, Rosei EA, Bardin T et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015; 33(9): 1729– 1741; discussion 1741. Dostupné z DOI: <http://dx.doi.org/10.1097/ HJH.0000000000000701>.

4. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–952. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(04)17018–9>.

5. Visseren FL, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ ehab484>.

6. O’Donnell MJ, Chin SL, Rangarajan S et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388(10046): 761– 775. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(16)30506– 2>.

7. Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012; 2012: 925046. Dostupné z DOI: <http://dx.doi.org/10.1155/2012/925046>.

8. Thomas F, Bean K, Guize L et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J 2002; 23(7): 528–535. Dostupné z DOI: <http://dx.doi.org/10.1053/euhj.2001.2888>.

9. Mancia G, Facchetti R, Bombelli M et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45(6): 1072–1077. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000165672.69176.ed>.

10. Wohlfahrt P, Krajčoviechová A, Bruthans J et al. [Hypertension and hypercholesterolemia in the Czech population]. Vnitr Lek 2016; 62(11): 863–867.

11. Čaprnda M, Novodomská K, Farkašovský J et al. Projekt TELMISTAR I – Sledovanie efektu telmisartanu a fixnej kombinácie telmisartan + amlodipín na dosahovanie cieľových hodnôt systolického a diastolického krvného tlaku na Slovensku u lekárov špecialistov. Kardiol Prax 2019; 17(3): 169–175.

12. Tóth Š, Pella D. Ako sme na tom s dosahovaním cieľových hladín LDL-cholesterolu na Slovensku u vysokorizikovej populácie: retrospektívna štúdia. AtheroRev 2022; 7(2): 112–117.

13. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res 2016; 118(4): 620–636. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.115.306301>.

14. Borghi C, Fogacci F, Agnoletti D et al. Hypertension and Dyslipidemia Combined Therapeutic Approaches. High Blood Press Cardiovasc Prev 2022; 29(3): 221–230. Dostupné z DOI: <http://dx.doi.org/10.1007/ s40292–022–00507–8>.

15. Strehlow K, Wassmann S, Böhm M et al. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000;32(6): 386–389. Dostupné z DOI: <http://dx.doi.org/10.3109/07853890008995944>.

16. Lee D-Y, Wauquier F, Eid AA et al. Nox4 NADPH oxidase mediates peroxynitrite- dependent uncoupling of endothelial nitric-oxide synthase and fibronectin expression in response to angiotensin II: role of mitochondrial reactive oxygen species. J Biol Chem 2013; 288(40): 28668–28686. Dostupné z DOI: <http://dx.doi.org/10.1074/jbc.M113.470971>.

17. Stulak JM, Lerman A, Caccitolo JA et al. Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. Atherosclerosis 2001; 154(1): 195–201. Dostupné z DOI: <http://dx.doi.org/10.1016/ s0021–9150(00)00462–7>.

18. Badoer E. The Carotid Body a Common Denominator for Cardiovascular and Metabolic Dysfunction? Front Physiol 2020; 11: 1069. Dostupné z DOI: <http://dx.doi.org/10.3389/fphys.2020.01069>.

19. Jackson R, Lawes CMM, Bennett DA et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005; 365(9457): 434–441. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)17833–7>.

20. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152(1): 56–64.

21. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484–491. Dostupné z DOI: <http://dx.doi. org/10.1016/j.ehj.2003.11.012>.

22. Williams B, Mancia G, Spiering W et al. [ESC Scientific Document Group]. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021–3104. Dostupné z DOI: <http:// dx.doi.org/10.1093/eurheartj/ehy339>.

23. Watanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and effects. Hypertension 2005; 45(2): 163–169. Dostupné z DOI: <http://dx.doi.org/10.1161/01.HYP.0000153321.13792.b9>.

24. Borghi C, Cicero AFG, Bacchelli S et al. Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation trial. Fundam Clin Pharmacol 2009; 23(5): 641–648. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1472–8206.2009.00704.x>.

25. Pitt B, O’Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87(9): 1058–1063. Dostupné z DOI: <http://dx.doi.org/10.1016/ s0002–9149(01)01461–8>.

26. Pitt B, Pepine C, O’Neill B et al. Modulation of ACE inhibitor efficacy on coronary endothelial dysfunction by low-density lipoprotein cholesterol [abstract 714–5]. J Am Coll Cardiol 1997; 29(Supplement 1): 70A.

27. Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41(24): 2313–2330. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz962>.

28. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: <http://dx.doi. org/10.1093/eurheartj/ehz455>.

29. Baigent C, Blackwell L, Emberson J et al. [Cholesterol Treatment Trialists’ (CTT) Collaboration]. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61350–5>.

30. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80(1): 106–107.

31. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326(7404): 1423. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.326.7404.1423.

32. Bautista LE. Blood pressure-lowering effects of statins: who benefits? J Hypertens 2009; 27(7): 1478–1484. Dostupné z DOI: <http://dx.doi. org/10.1097/HJH.0b013e32832b1e78>.

33. Correa V, Gus M, Fuchs FD. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? Expert Rev Cardiovasc Ther 2010; 8(6) : 775–779. Dostupné z DOI: <http://dx.doi. org/10.1586/erc.10.59>.

34. Feldstein CA. Statins in hypertension: are they a new class of antihypertensive agents? Am J Ther 2010; 17(3): 255–262. Dostupné z DOI: <http://dx.doi.org/10.1097/MJT.0b013e3181c0695e>.

35. Pelat M, Balligand J-L. Statins and hypertension. Semin Vasc Med 2004; 4(4): 367–375. Dostupné z DOI: <http://dx.doi.org/ 10.1055/s-2004–869593>.

36. Briasoulis A, Agarwal V, Valachis A et al. Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich) 2013; 15(5): 310–320. Dostupné z DOI: <http://dx.doi. org/10.1111/jch.12081>.

37. Radhoe SP, Boersma E, Bertrand M et al. The Effects of a Perindopril- Based Regimen in Relation to Statin Use on the Outcomes of Patients with Vascular Disease: a Combined Analysis of the ADVANCE, EUROPA, and PROGRESS Trials. Cardiovasc Drugs Ther 2022. Dostupné z DOI: <http:// dx.doi.org/10.1007/s10557–022–07384–2>.

38. Borghi C, Levy BI. Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutr Metab Cardiovasc Dis 2022; 32(4): 815–826. Dostupné z DOI: <http://dx.doi.org/10.1016/j. numecd.2021.11.015>.

39. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte. 165.10.1147>.

40. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55(2): 399–407. Dostupné z DOI: <http://dx.doi. org/10.1161/HYPERTENSIONAHA.109.139816>.

41. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin 2017; 33(10): 1783–1787. Dostupné z DOI: <http://dx.doi.org/10.1080/030079 95.2017.1367275>.

42. Rosolová H. Advances of the contemporary treatment of hypertension and hypercholesterolemia by a new fixed combination. Vnitr Lek 2022; 68(1): 64–67.

43. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92(2): 152–160. Dostupné z DOI: <http://dx.doi.org/10.1016/s0002–9149(03)00530–7>.

44. Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147(4): 705–713. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ahj.2003.10.004>.

45. Ballantyne CM, Raichlen JS, Cain VA. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008; 52(8): 626–632. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2008.04.052>.

46. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/ dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100(8): 1245–1248. Dostupné z DOI: <http:// dx.doi.org/10.1016/j.amjcard.2007.05.044>.

47. Crouse JR, Raichlen JS, Riley WA et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007; 297(12): 1344–1353. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.297.12.1344>.

48. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295(13): 1556–1565. Dostupné z DOI: <http://dx.doi. org/10.1001/jama.295.13.jpc60002>.

49. Puri R, Nissen SE, Shao M et al. Antiatherosclerotic effects of longterm maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. Arterioscler Thromb Vasc Biol 2014; 34(11): 2465–2472. Dostupné z DOI: <http://dx.doi.org/10.1161/ATVBAHA. 114.303932>.

50. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195–2207. Dostupné z DOI: <http://dx.doi. org/10.1056/NEJMoa0807646>.

51. Pitt B, Loscalzo J, Monyak J et al. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol 2012; 109(9): 1239–1246. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2011.12.015>.

52. Leiter LA, Rosenson RS, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis 2007; 194(2): e154–164. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis. 2006.12.001>.

53. Rahhal A, Khir F, Orabi B et al. A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data. Curr Probl Cardiol 2022; 47(7): 100956. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cpcardiol.2021.100956>.

54. Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther 1993; 15(5): 810–818.

55. Yusuf S, Sleight P, Pogue J et al. [Heart Outcomes Prevention Evaluation Study Investigators]. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342(3): 145–153. Dostupné z DOI: <http://dx.doi.org/10.1056/ NEJM200001203420301>.

56. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253–259.

57. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349(9069): 1857–1863.

58. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342(8875): 821–828.

59. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349(9064): 1493–1497. Dostupné z DOI: <http://dx.doi.org/10.1016/ s0140–6736(97)04442–5>.

60. Han SH, Chung W-J, Kang WC et al. Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound. Int J Cardiol 2012; 158(2): 217–224. Dostupné z DOI: <http://dx.doi. org/10.1016/j.ijcard.2011.01.030>.

61. ROSURAMLON 10 MG/10 MG. Súhrn charakteristických vlastností lieku. Dostupné z WWW: <https://www.liekinfo.sk/liek-rosuramlon-10-mg- 10-mg-cps-dur-60x10-mg-10-mg-(blis-opa-al-pvc-al)-120873-spc>.